Breakdown | |||||
TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
25.47M | 57.31M | 19.75M | 38.70M | 15.63M | 19.50M | Gross Profit |
16.14M | 50.40M | 11.95M | 32.00M | -77.33M | -31.02M | EBIT |
-8.58M | -10.47M | -88.87M | -80.07M | -100.84M | -70.45M | EBITDA |
-11.16M | 1.43M | -80.08M | -72.94M | -99.01M | -66.02M | Net Income Common Stockholders |
-7.32M | -8.12M | -92.72M | -79.31M | -104.92M | -69.54M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
83.58M | 11.52M | 61.05M | 143.04M | 93.89M | 125.08M | Total Assets |
140.60M | 35.38M | 97.55M | 192.36M | 139.88M | 174.20M | Total Debt |
13.93M | 12.23M | 50.58M | 45.05M | 27.14M | 14.62M | Net Debt |
-23.93M | 707.00K | 18.39M | 20.07M | 1.92M | -70.83M | Total Liabilities |
44.47M | 31.17M | 112.68M | 126.70M | 80.54M | 71.17M | Stockholders Equity |
96.14M | 4.21M | -15.13M | 65.66M | 59.34M | 103.03M |
Cash Flow | Free Cash Flow | ||||
-23.92M | -42.02M | -92.22M | -34.38M | -91.19M | -34.89M | Operating Cash Flow |
-23.92M | -41.82M | -89.02M | -30.39M | -83.80M | -25.24M | Investing Cash Flow |
8.00K | 29.09M | 95.32M | -62.44M | -34.66M | -39.72M | Financing Cash Flow |
27.00M | -9.12M | -265.00K | 92.59M | 58.90M | 65.70M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
49 Neutral | $6.84B | 0.05 | -53.14% | 2.48% | 24.49% | -3.26% | |
44 Neutral | $118.14M | ― | -53.54% | ― | 145.37% | 57.01% | |
42 Neutral | $115.74M | ― | -54.21% | ― | -78.55% | -0.92% | |
41 Neutral | $63.37M | ― | 41.08% | ― | -0.55% | 49.85% | |
36 Underperform | $7.00 | ― | -192.88% | ― | -49.41% | 78.46% |
Molecular Templates announced significant changes in its leadership, with multiple resignations from its Board of Directors and the resignation of Dr. Eric E. Poma from several executive roles. These changes are part of a strategic decision to wind down the company’s operations, with Craig Jalbert appointed as the sole director to oversee this process. The company has cautioned stakeholders about the speculative nature of trading its securities, indicating that current trading prices may not reflect actual value and that investors are unlikely to realize returns on their investments.
Jason Kim has resigned as the Company’s President, CFO, and Treasurer, effective December 8, 2024, with no disagreements or severance involved. Kim will continue to consult until year-end while his stock options vest. Eric Poma, the CEO and Chief Scientific Officer, steps in as Interim CFO, leveraging his extensive experience in biotechnology and company leadership to guide the financial helm during this transitional period.